Washington,
D.C. 20549
FORM
6-K
REPORT
OF
FOREIGN ISSUER
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For
the month of January 2006
Commission
File Number 000-51122
pSivida
Limited
(Translation
of registrant’s name into English)
Level
12
BGC Centre
28
The
Esplanade
Perth
WA
6000
(Address
of principal executive offices)
(Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F).
Form
20-F
ý Form
40-F o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):
Indicate
by check mark whether the registrant by furnishing the information contained
in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
o No
ý
If
"Yes"
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82- ___.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant,
pSivida Limited, has duly caused this report to be signed on its behalf by
the
undersigned, thereunto duly authorized.
Date:
January 12,
2006
|
pSivida
Limited
|
||
| |
|
|
| By: | /s/ Aaron Finlay | |
|
Aaron
Finlay
Chief
Financial Officer and Company Secretary
|
||
EXHIBIT
INDEX
|
EXHIBIT
99.1:
|
New
Non-executive Director - Australian Institutional Investment
Focus
|
Exhibit
99.1
| ASX/MEDIA RELEASE |
12
January
2006
|
New
Non-executive Director
Australian
Institutional Investment Focus
Global
bio-nanotech company pSivida Limited (ASX:PSD,
NASDAQ:PSDV, Xetra:PSI)
is
pleased to announce the appointment of Ms. Heather Zampatti as a Non-executive
Director of the Company, based in Perth, Australia.
Ms.
Zampatti is the National Head of Wealth Management, Australia for Bell Potter
Securities, an Australian-owned private investment adviser and top 10 broker
by
trading volume on the Australian Stock Exchange. Ms Zampatti has over 20 years
experience in investment advising and her expertise in stockbroking and
financial investment planning is widely acknowledged in the Australian
investment community.
Ms.
Zampatti was educated at the University of Western Australia and holds a
Bachelor of Science (BSc) and Diploma of Education (Dip Ed). She lectures for
the Australian Stock Exchange and the Securities Institute of Australia and
gives many public seminars. In addition to this appointment, Ms. Zampatti is
a
board member of the Princess Margaret Hospital for Children Foundation and
is a
director of the Australian Institute of Management (WA) and Osteoporosis
Australia.
The
appointment of Ms. Zampatti to the pSivida board replaces Ms. Alison Ledger
who
has stepped down after 18 months of service to focus on new career initiatives.
We wish Alison well in her future endeavours and thank her for her valuable
contribution.
“With
the
acquisition of Control Delivery Systems (now pSivida Inc.) in the United States
now complete, the Company can focus on further commercialisation of our platform
technologies in new markets and territories,” said pSivida CEO and Managing
Director, Mr. Gavin Rezos. “The addition of Heather to the pSivida board will
broaden the Company’s relationships with Australian institutions and follows the
appointments of two US based Non-executive Directors in July 2005 to raise
the
company’s awareness in the important US market.”
pSivida
has three directors based in the US, two directors based in the UK and two
in Australia. There is a majority of independent directors.
pSivida
also recently announced several new evaluation agreements for the
Company’s drug delivery technologies and now has agreements with three of
the top five pharmaceutical companies in the world.
-ENDS-
|
pSivida
Limited
Brian
Leedman
Investor
Relations
pSivida
Limited
Tel:
+ 61 8 9226 5099
brianl@psivida.com
|
US
Public Relations
Beverly
Jedynak
President
Martin
E. Janis & Company, Inc
Tel:
+1 (312) 943 1100 ext. 12
bjedynak@janispr.com
|
UK
& Europe Public Relations
Mark
Swallow / Helena Podd
Citigate
Dewe Rogerson
Tel:
+44 (0)20 7638 9571
mark.swallow@citigatedr.co.uk
|
NOTES
TO EDITORS:
pSivida
is a global bio-nanotech company committed to the biomedical sector and the
development of drug delivery products in particular in oncology and
ophthalmology.
pSivida
owns or has the exclusive rights to use the intellectual property pertaining
to
BrachySil™, Medidur™, Retisert™ and Vitrasert®.
The
company’s IP portfolio consists of 70 patent families, 74 granted patents and
over 290 patent applications.
pSivida
owns the rights to develop and commercialise a modified form of silicon
(porosified or nano-structrured silicon) known as BioSilicon™, which has
applications in drug delivery, wound healing, orthopaedics, and tissue
engineering. pSivida has granted an exclusive licence to its subsidiary, AION
Diagnostics Limited to develop and commercialise diagnostic products using
BioSilicon™, and has also granted an exclusive licence to its subsidiary,
pSiNutria Limited to develop and commercialise food technology applications
using BioSilicon™.
pSivida
conducts its operations from offices and facilities near Boston in
Massachusetts, Malvern in the United Kingdom, Perth in Western Australia and
Singapore.
pSivida
is listed on NASDAQ (PSDV),
the
Australian Stock Exchange (PSD)
and in
Germany on the Frankfurt Stock Exchange on the XETRA system (German Symbol:
PSI. Securities Code (WKN) 358705).
pSivida is a founding member of the NASDAQ Health Care Index and the Merrill
Lynch Nanotechnology Index.
The
Company's largest shareholder and a strategic partner is QinetiQ, a leading
international defence, security and technology company, formed in July 2001
from
the UK Government's Defence Evaluation & Research Agency
(DERA). QinetiQ was instrumental in discovering BioSilicon(TM)
and
pSivida enjoys a strong relationship with it having access to its cutting edge
research and development facilities. For more information visit www.QinetiQ.com
For
more
information, visit www.psivida.com
This
document contains forward-looking statements that involve risks and
uncertainties. The statements are indicated by the use of words such as
"believes", "expects", "anticipates" and similar words and phrases.
Although we believe that the expectations reflected in such forward-looking
statements are reasonable at this time, we can give no assurance that such
expectations will prove to be correct. Given these uncertainties, readers are
cautioned not to place undue reliance on such forward-looking statements. Actual
results could differ materially from those anticipated in these forward-looking
statements due to many important factors including: our failure to develop
applications for BioSiliconTM
due to
regulatory, scientific or other issues, our inability to successfully integrate
CDS’ operations and employees; the failure of the CDS’ products to achieve
expected revenues and the combined entity’s inability to develop existing or
proposed products. Other reasons are contained in cautionary statements in
the
Registration Statement on Form 20-F filed with the U.S. Securities and Exchange
Commission, including, without limitation, under Item 3.D, "Risk Factors"
therein. We do not undertake to update any oral or written forward-looking
statements that may be made by or on behalf of pSivida.